Ecological and evolutionary dynamics to design and improve ovarian cancer treatment

GYQ Han, M Alexander, J Gattozzi… - Clinical and …, 2024 - Wiley Online Library
Ovarian cancer ecosystems are exceedingly complex, consisting of a high heterogeneity of
cancer cells. Development of drugs such as poly ADP‐ribose polymerase (PARP) inhibitors …

A combination of protein phosphatase 2A inhibition and checkpoint immunotherapy: a perfect storm

MC Clark, RO Lu, WS Ho, MH Dias… - Molecular …, 2024 - Wiley Online Library
Immune checkpoint blockade has emerged as a potent new tool in the war on cancer.
However, only a subset of cancer patients benefit from this therapeutic modality, sparking a …

[HTML][HTML] Pembrolizumab with bevacizumab and cyclophosphamide for the treatment of recurrent ovarian clear cell carcinoma: A case series

SM Glynn, S Gaillard, RL Stone, AN Fader… - Gynecologic Oncology …, 2024 - Elsevier
Introduction Treatment for recurrent ovarian clear cell carcinoma (OCCC) is clinically
challenging as response rates to traditional chemotherapy are low, and recurrence rates are …

Oxabicycloheptanes for modulation of immune response

JS Kovach, Z Zhuang, SCW Ho, H Wang… - US Patent 12,168,008, 2024 - Google Patents
2019-06-19 Assigned to THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE
SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES reassignment THE …